
News|Videos|November 14, 2023
Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA
Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5







































